GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gemina Laboratories Ltd (XCNQ:GLAB) » Definitions » Debt-to-Revenue

Gemina Laboratories (XCNQ:GLAB) Debt-to-Revenue : N/A (As of Jan. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Gemina Laboratories Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Gemina Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.28 Mil. Gemina Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jan. 2024 was C$0.21 Mil. Gemina Laboratories's annualized Revenue for the quarter that ended in Jan. 2024 was C$0.00 Mil.


Gemina Laboratories Debt-to-Revenue Historical Data

The historical data trend for Gemina Laboratories's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gemina Laboratories Debt-to-Revenue Chart

Gemina Laboratories Annual Data
Trend Jan21 Jan22 Jan23 Jan24
Debt-to-Revenue
N/A N/A N/A N/A

Gemina Laboratories Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

Competitive Comparison of Gemina Laboratories's Debt-to-Revenue

For the Biotechnology subindustry, Gemina Laboratories's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gemina Laboratories's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gemina Laboratories's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Gemina Laboratories's Debt-to-Revenue falls into.



Gemina Laboratories Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Gemina Laboratories's Debt-to-Revenue for the fiscal year that ended in Jan. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.279 + 0.206) / N/A
=N/A

Gemina Laboratories's annualized Debt-to-Revenue for the quarter that ended in Jan. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.279 + 0.206) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Jan. 2024) Revenue data.


Gemina Laboratories Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Gemina Laboratories's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Gemina Laboratories (XCNQ:GLAB) Business Description

Traded in Other Exchanges
Address
3800 Gilmore Mall, Suite 302, Burnaby, BC, CAN, V5G 4R8
Gemina Laboratories Ltd is a biotechnology company that operates in the In Vitro Diagnostics (IVD) market under the name Gemina Labs. The company endeavors to develop novel surface functionalization chemistries for the detection of pathogens and biomarkers.
Executives
James Damian Tansey Director

Gemina Laboratories (XCNQ:GLAB) Headlines

No Headlines